Holdings
Saturn V Capital Management LP
As of Sep 30, 2026, Saturn V Capital Management LP reported 21 positions worth US$596M. Largest: Amylyx Pharmaceuticals, Inc., Abivax SA and Immix Biopharma, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. | 4.47M | US$130M | −153K | Sep 30, 2026 |
| Abivax SA | 529K | US$52.4M | +10,448 | Sep 30, 2026 |
| Immix Biopharma, Inc. | 4.66M | US$48.5M | +2,686 | Sep 30, 2026 |
| Vaxcyte, Inc. | 772K | US$43.9M | −80,656 | Sep 30, 2026 |
| Celcuity Inc. | 514K | US$40.9M | +144K | Sep 30, 2026 |
| Disc Medicine, Inc. | 613K | US$40.1M | +87,931 | Sep 30, 2026 |
| Candel Therapeutics, Inc. | 3.48M | US$36.3M | +173K | Sep 30, 2026 |
| Monopar Therapeutics Inc. | 312K | US$24.9M | +374 | Sep 30, 2026 |
| Vir Biotechnology, Inc. | 2.04M | US$22.8M | +1.27M | Sep 30, 2026 |
| Trevi Therapeutics, Inc. | 1.57M | US$22.5M | +522K | Sep 30, 2026 |